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Abstract: Lentiviral vectors have demonstrated promising results in clinical trials that 
target cells of the hematopoietic system. For these applications, they are the vectors of 
choice since they provide stable integration into cells that will undergo extensive 
expansion in vivo. Unfortunately, integration can have unintended consequences including 
dysregulated cell growth. Therefore, lentiviral vectors that do not integrate are predicted to 
have a safer profile compared to integrating vectors and should be considered for 
applications where transient expression is required or for sustained episomal expression 
such as in quiescent cells. In this review, the system for generating lentiviral vectors will 
be described and used to illustrate how alterations in the viral integrase or vector Long 
Terminal Repeats have been used to generate vectors that lack the ability to integrate.  
In addition to their safety advantages, these non-integrating lentiviral vectors can be used 
when persistent expression would have adverse consequences. Vectors are currently in 
development for use in vaccinations, cancer therapy, site-directed gene insertions, gene 
disruption strategies, and cell reprogramming. Preclinical work will be described that 
illustrates the potential of this unique vector system in human gene therapy.  
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1. Introduction 
Gene therapy using lentiviral vectors (LV) holds great promise for the treatment of a wide variety 
of disorders. The major advantage of these vectors is their ability to stably integrate into target cells, 
thus providing genetic modification of the cell and all of its progeny. Other advantages of LVs include 
low immunogenicity, a lack of prior immunity, a relatively large packaging capacity, and an ability to 
be pseudotyped with alternative envelopes thus altering vector tropism [1–8]. To date, the predominant 
use of these vectors has been ex vivo modification of hematopoietic stem cells, T cells or other targets 
where the transduced cell is expected to expand in vivo. For example, early clinical trials have shown 
evidence of disease correction or delay of onset including treatment for thalassemia, adrenoleukodystrophy, 
chronic lymphocytic leukemia, metachromatic leukodystrophy, and Wiskott Aldrich syndrome [9–13].  
A number of potential lentiviral vector applications will not require stable integration, including 
their use in immunizations, cytotoxic cancer therapies, or delivery to sites such as the central nervous 
system. In these settings, it may be advantageous to express the vector transgenes episomally to 
mitigate the risk of insertional mutagenesis. The phenomenon of insertional mutagenesis occurs when 
regulatory regions in the vector activate surrounding genes involved with cell growth or the integration 
disrupts genes resulting in growth dysregulation or genetic instability [9,14,15]. 
In this review, we will reveal how the unique life-cycle of the lentivirus permits the design of  
non-integrating lentiviral vectors. Specifically, modifying integrase and/or its binding site allows the 
development of episomally expressed vectors that retain the ability to infect target cells and express 
the transgene(s) of choice. We also describe the use of non-integrating lentiviral vectors in gene 
therapy applications, their limitations, and current advances intended to improve upon clinical utility.  
1.1. Lentiviral Vector Design 
Lentiviral vectors derived from the human immunodeficiency virus type 1 (HIV-1) have the ability 
to integrate efficiently into quiescent or non-dividing cells [16]. As depicted in Figure 1A, LVs were 
advanced by removing non-essential sequences and genomic regions involved with viral replication 
and virulence from the wild-type lentiviral genome (e.g., nef, vif, vpr, and vpu). The end result is a 
replication defective vector containing the necessary elements for packaging and processing but still 
capable of integration [17,18]. Vector particles are generated using a series of plasmids that express 
the vector genome and the viral proteins required for particle formation. The technology for packaging 
vector particles continues to evolve, but the commonly used “third generation” systems utilize a series 
of four vector plasmids that are introduced into cells by transient transfection (Figure 1B) [19].  
In addition to the transgene plasmid containing the vector genome, the system uses a plasmid 
expressing the gag and pol gene regions that produce the HIV-1 structural proteins required for capsid 
formation and genome integration. A plasmid expressing HIV-1 rev is also included to activate the rev 
responsive element engineered into the transgene and gag/pol plasmids. This facilitates nuclear 
transport and is also included as a safety feature. The fourth plasmid expresses an envelope glycoprotein 
that engages receptors on the target cells. As the native HIV-1 glycoprotein is generally restricted to 
CD4 positive cells, investigators utilize alternative envelopes, most commonly the Vesicular Stomatitis 
Virus G glycoprotein [20] (VSV-G), to facilitate uptake into a wide variety of species and cell types. 
Biomedicines 2014, 2 16 
 
The use of multiple plasmids and the requirement for rev are included to minimize recombination 
events that would lead to the development of a replication competent virus.  
Figure 1. Schematic of HIV-1 and Third Generation Lentiviral Packaging System.  
(A) The HIV-1 Virus contains three gene regions gag, pol, and env along with accessory 
proteins and the flanking Long Terminal Repeats (LTR); (B) The lentiviral components 
found in the four plasmids used in generating third generation lentiviral vectors. The vector 
plasmid contains a self-inactivating 3' LTR (SIN-LTR), a Rev responsive element (RRE),  
a central polypurine tract (cPPT), and the Woodchuck Hepatitis Virus Post-Transcriptional 
Response Element. The psi sequence (Ψ) allows for efficient incorporation of the vector 
RNA genome into particles. In this schematic, the CMV early promoter is used for 
transgene expression but other promoters are commonly substituted. The packaging plasmid 
expresses the gag and pol gene regions of HIV-1 which encode proteins required for virion 
formation and vector processing. This plasmid also contains a RRE. A plasmid expressing 
rev is provided to facilitate nuclear transport of RRE containing transcripts. The fourth 
plasmid is the envelope plasmid. Lentiviral vectors are commonly pseudotyped with the 
Vesicular Stomatitis Virus G glycoprotein (VSV-G) as an alternative to the native HIV-1 
envelope to increase the range of cell types and animal species susceptible to vector transduction. 
 
For efficient integration, viral particles must contain the proteins encoded in the HIV-1 pol region 
which are necessary for vector processing including reverse transcriptase, polymerase and protease. 
Cellular proteins important in efficient transduction include cyclophilin A and integrase interactor 1 
which are also packaged within the capsid structure [21–28]. Vector particles also contain two copies 
of a single-stranded RNA genome. As shown in Figure 1A, each end of the RNA genome contains a 
long-terminal repeat (LTR), with an untranslated 5' and 3' segment (U5/U3) flanking a repeat region 
(R). Most vectors retain certain components of the HIV-1 genome including the psi signal that 
markedly increases the packaging of the genome into the mature virion. A short portion of gag 
sequence which is critical for generating high titer vector is also retained.  
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The transgene plasmid contains the minimal components of HIV-1 required for vector production 
and integration. The transgene of interest is 3' to a promoter element that regulates expression. The 
choice of the specific promoter is driven by the intended use. Common examples include tissue 
specific promoters, enhancers, insulators, or microRNA regions. Additional elements are added to 
increase vector production and/or expression including a polypurine tract [29,30] and the Woodchuck 
Hepatitis Virus Post-Transcriptional Response Element (WPRE) [31,32]. 
An important safety feature of most LVs is the inclusion of a Self-Inactivating Long Terminal 
Repeat (SIN-LTR). This feature minimizes the risk of producing a replication-competent lentivirus by 
recombination with wild-type viruses. The mechanism involves taking advantage of the normal 
replication cycle of HIV-1. In wild-type HIV-1, the viral promoter is within the U3 region of the 5' LTR 
and is required to generate the full length viral transcript. The U3 region is also present in the 3' LTR 
but is not essential in the DNA form of the virus. During viral replication, the RNA genome is reverse 
transcribed and the 3' LTR is utilized in formation of both the 5' and 3' LTR of the daughter virus. By 
incorporating a large deletion into the U3 region of the 3' LTR any progeny will contain two 
inactivated LTR after reverse transcription [17,33]. Transgene expression is dependent solely on the 
internal promoter (for example, the CMV promoter engineered into the vector plasmid as illustrated  
in Figure 1B). 
1.2. Retaining Key Parts of the Life Cycle during Non-Integrating Lentiviral Vector Design 
LVs are generated by introducing the transgene and packaging plasmids into cells, most commonly 
HEK293T cells (Figure 2). Vector supernatant is collected from the media and typically contains 
between 105 and 107 infectious units per milliliter. This is dependent on the vector design as the 
addition or deletion of elements to vector design can affect vector titer. LV can be concentrated by 
ultracentrifugation and clinical vector products are usually purified using a combination of 
chromatography, tangential flow filtration and diafiltration [34–36]. 
In order to effectively transduce a target cell, both integrating and non-integrating lentiviral vectors 
(NILV) must retain the ability to readily enter the cell, form a pre-integration complex, be transported 
into the nucleus and efficiently express its genetic payload. Depending on the envelope pseudotype 
used the membrane bound LV particles enter cells either by direct fusion with the plasma membrane [2] 
or via a receptor-mediated endosomal pathway [20]. In the direct fusion pathway the LV is uncoated 
upon entry to release the viral contents into the cytoplasm. This allows for reverse transcription of the 
viral RNA into linear cDNA and development of the pre-integration complex (PIC). The PIC consists 
of the reverse transcribed viral cDNA complexed with integrase, matrix, reverse transcriptase, and 
nucleocapsid proteins [37–40]. The endosomal pathway is dependent upon the pH within the 
endosome for membrane fusion, subsequent uncoating, and PIC formation within the cytoplasm.  
The transportation of the PIC to the nucleus is not completely understood, but is believed to occur by 
an ATP-dependent process [41] via nucleoporins [42,43] using nuclear localization signals and cellular 
transport mechanisms [44]. Certain of the known localization signals have been removed during LV 
design; nevertheless, the transduction of quiescent cells by LV is well documented.  
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Figure 2. Generation of Lentiviral Vector by Transient Transfection. The four packaging 
plasmids are transfected into cells that have a high capacity for vector production. The 
most commonly used cell line is HEK293T. Maximal vector production occurs 48–72 h after 
transfection. The vector particles are released into the media which is collected and 
clarified of cell debris. Vector particles can be further purified and/or concentrated. 
 
Understanding the processing of the LV cDNA after reverse transcription is important when 
designing NILV. Normally the linear LV cDNA generated during reverse transcription enters the 
nucleus with the linear 2-LTR form [45] representing the preferred substrate for integration [46,47].  
A small portion of LV genomes can persist episomally as linear cDNA, 2-LTR circular forms or 1-LTR 
circular forms. The majority of 2-LTR circles are formed through non-homologous end-joining of the 
5' and 3' LTRs [46,48,49]. The majority of 1-LTR circles are formed by homologous recombination 
between the LTRs [49–54], as an aberrant product of incomplete reverse transcription [55–59], or 
through alternative mechanisms such as autointegration [60]. It is these episomal forms that allow for 
the stable expression of the vector transgene without integration in non-dividing cells [61–64]. 
2. Designing Non-Integrating Lentiviral Vectors 
2.1. Inhibiting Integration/Developing NILV 
When designing NILV it is important that modifications maintain the vectors ability to enter their 
target cells, perform reverse transcription, transport the PIC into the nucleus and efficiently express 
their transgene product. This entails selectively inhibiting or altering only the aspects of the vectors 
lifecycle that lead to integration. As integrase-mediated catalysis is the primary means of integration 
for LV, the inhibition of its function is necessary in the development of NILV. 
Normally, integration into the target cell’s genome is mediated by the viral integrase. This protein 
first binds to the viral cDNA at attachment sites located within the U3 region of the 5' LTR and the U5 
region of the 3' LTR [65–68]. Integrase processes the 3' ends of the viral cDNA leaving a CA 
dinucleotide overhang [69,70] and then attaches the recessed ends to the 5' phosphorylated ends of a 
double-stranded cut made in the target genome. Integrase then repairs the gaps resulting in a 5 base-pair 
repeat flanking the inserted vector genome [70,71]. Figure 3 shows the three general points that can be 
targeted in developing a NILV; mutations in the integrase protein that alter its ability to process the 
target cell chromosomal DNA or alteration in the vector LTRs that prevent integrase from attaching to 
the 5' or 3' LTR.  
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Figure 3. Targets for Creation of Non-Integrating Lentiviral Vectors. Three strategies have 
been devised to generate non-integrating vectors. Mutations are generated in (1) a 12 base-pair 
region of the U3 region of the 5' LTR; (2) an 11 base-pair region of the U5 region of the 
vector’s 3' LTR; or (3) point mutations in the integrase protein that interfere with processing 
of the vector DNA. This depiction is simplified as integrase and the vector DNA are part of 
a complex of proteins. 
 
The most common target for inhibiting viral integration is mutation of the integrase protein 
producing integrase-defective lentiviral vectors. LV integrase is coded for by the HIV-1 Pol region and 
the region cannot be deleted as it encodes other critical activities including reverse transcription, 
nuclear import, and viral particle assembly [72,73]. Mutations in pol that alter the integrase protein fall 
into one of two classes: those which selectively affect only integrase activity (Class I); or those that 
have pleiotropic effects (Class II) [74]. Mutations throughout the N and C terminals and the catalytic 
core region of the integrase protein generate Class II mutations that affect multiple functions including 
particle formation and reverse transcription [74–76]. However, class II mutations are not suitable when 
designing NILVs because they disrupt functions that are critical for vector processing and expression.  
Class I mutations limit their affect to the catalytic activities, DNA binding, linear episome 
processing and multimerization of integrase [77]. The most common Class I mutation sites are a triad 
of residues at the catalytic core of integrase, including D64, D116, and E152 [78,79]. Each mutation 
has been shown to efficiently inhibit integration with a frequency of integration up to four logs below 
that of normal integrating vectors while maintaining transgene expression of the NILV [61,80,81]. 
Another alternative method for inhibiting integration is mutations in the integrase DNA attachment 
site (LTR att sites) within a 12 base-pair region of the U3 or an 11 base-pair region of the U5 regions 
at the terminal ends of the 5' and 3' LTRs, respectively [61,68,80,82,83]. These sequences include the 
conserved terminal CA dinucleotide which is exposed following integrase-mediated end-processing. 
Single or double mutations at the conserved CA/TG dinucleotide result in up to a three to four log 
reduction in integration frequency [80]; however, it retains all other necessary functions for efficient 
viral transduction.  
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2.2. Minimizing Illegitimate Integration 
While NILV can significantly reduce the frequency of integration there still remains a low level of 
vector integration [61,62,80,81,84–89]. Integration associated with NILV has been studied using 
insertion site analysis and high-throughput sequencing. These analyses indicate that the integration 
observed is not integrase-mediated as the insertion sites lack the canonical features of LTR  
end-processing including the five base-pair repeat of genomic DNA flanking at the site of vector 
insertion [80,85,88,90,91]. The vector inserts also vary with some containing fully intact sequence, 
truncations at the terminal ends of the LTRs, or insertions/deletions of genomic DNA flanking the 
vector. A significant number of these illegitimate integrations are occurring at sites of chromosomal 
breakage and are mediated by non-homologous end-joining mechanisms [90,92]. It may be possible to 
impede illegitimate integration of NILV by inhibition of cellular factors in the double-strand break 
(DSB) repair pathway. In a recent study by Koyama and colleagues, introduction of an ataxia 
telangiectasia mutated specific inhibitor (KU55933) consistently blocked DSB-specific integration in 
wild-type and integrase deficient LV [90]. Whether or not inhibitors to DNA repair can be used 
clinically to limit non-integrase mediated integration remains to be determined.  
Another method for further reducing the frequency of illegitimate integration is limiting the linear 
form of the vector DNA. Linear DNA has been shown to integrate much more efficiently than 
supercoiled DNA [46,47]. The linear form also appears to be the preferred substrate for both integrase 
and non-integrase-mediated insertion. One approach has been to limit linear 2-LTR episomal forms by 
inducing the formation of circular episomal forms. For example, Kantor and colleagues have shown 
that deleting the vectors 3' polypurine tract (PPT) results in aberrant reverse transcription leading to the 
preferential formation of 1-LTR circular episomes and a reduction in linear forms [58]. Using this 
strategy they were able to reduce the frequency of integration by 10-fold when using an integrating 
vector. Of relevance to NILV, this modification reduced the frequency of integration of an integrase 
deficient LV by another 3-fold over integrase deficient LV without the modification. As newer 
modifications are developed to reduce integration they will need to be tested experimentally to ensure 
there is no reduction in the level of transgene expression. 
It should be noted that LTR att site mutations have been directly compared to point mutations in 
integrase. The consensus is that mutations to integrase provide a greater reduction in the frequency of 
integration. Yanez-Munoz et al. estimated the frequency of reversion mutations in NILV to reach 
1/815 [89]. The point mutations to LTR att sites could carry a higher rate of reversions but whether 
LTR att site mutations with larger deletions will reduce the frequency of illegitimate integration 
remains to be determined. Interestingly, while mutations to integrase and the LTR att sites 
independently inhibit integration efficiently, some studies suggest there are no synergistic effects upon 
combining these mutations to further reduce integration by a vector [61,80]. 
2.3. Optimization of NILV Expression  
NILV are associated with a significantly reduced level of transgene expression as compared to a 
normal integrating LV [16,58,61,62,64,84,87,93–95]. This remains a key issue in developing clinically 
effective NILV. One approach to improve expression would be the introduction of stronger promoter 
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or enhancer elements; but this approach may alter their safety profile by increasing the chance of 
insertional mutagenesis for NILV that are incorporated into cellular genomes through illegitimate 
integration [14,15,96–100]. Several studies now show that vectors with less potent enhancer or 
promoter elements do have an improved safety profile [101–106]. 
A second approach is removing or reducing inhibitors to episomal transgene expression. Bayer et al. 
have shown that removal of cis-acting sequences within the U3 region of the vectors LTR improves 
episomal transgene expression by nearly 3-fold [64]. However, other mechanisms of episomal inhibition 
may be involved because expression was still below that of the normal, integrating LV control.  
A third approach to improved expression is the inhibition of cellular restriction factors. Utilizing the 
simian immunodeficiency virus auxiliary protein Vpx enabled the inhibition of the myeloid-lineage 
specific protein SAMHD1. SAMHD1 restricts an early step in the viral life cycle and inhibiting this 
protein greatly improves the transduction of human and simian myeloid cells [107–110]. Furthermore, 
applying this inhibition in conjunction with integrase deficient LV preparations was able to improve 
episomal expression to levels observed with normal integrating LV [111,112]. Other approaches for 
improving transgene expression include codon optimization to improve protein production and 
potency [113,114] and the use of histone deacetylase inhibitors for transgene activation [115]. 
Combining modifications that increasing transgene expression and reduce integration will be 
needed to maximize the safety profile of NILV. If expression is low, a higher number of NILV will be 
required per cell to obtain the therapeutic benefit. The higher numbers of vector episomes will in turn 
increase the chance of illegitimate integration. For certain gene therapy trials, such as those using ex vivo 
gene transfer of CD34+ hematopoietic cells, the number of cells treated may exceed 5 × 108 cells for 
an adult. Even with a four log reduction in integration, a significant number of cells will contain 
integrated proviruses. Therefore efforts to minimize integration and optimizing expression should be 
considered for both therapeutic and safety reasons.  
3. Prospects and Applications 
Several modifications have been researched to improve the safety and utility of NILV for future 
clinical applications. These improvements facilitate the development of NILV for the treatment of 
genetic diseases, infectious diseases, and as important mediators of cell reprogramming. NILV are 
being developed for clinical applications where integration is not required in order to minimize the risk 
of genotoxicity by insertional mutagenesis. They also are of interest where transient expression is 
preferred over sustained gene expression. These applications include vaccinations, cell-type and 
lineage differentiation, as donor templates for homologous recombination in site-directed integration 
systems, and as delivery systems for cytotoxic cancer therapies. NILV are also being considered for 
gene transfer into slowly growing or non-dividing tissues where persistent episomal expression can 
provide a long-lasting therapeutic effect. An overview of vector components for many of these 
applications is provided in Table 1. 
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Table 1. Summary of elements included in non-integrating lentiviral vectors (NILV) design. The far right column categorizes the applications 
depending on the intended purpose. The column of NILV Modifications provides the integrase mutations or Δatt (LTR integrase attachment 
site mutation) used to inhibit integration. Other components of the vector systems are provided in subsequent columns. Abbreviations: iPS, 
induced pluripotent stem (cell); VSV-G, Vesicular Stomatitis Virus glycoprotein (IND and NJ serotypes if specified); HCV-E1E2-G, Hepatitis 
C Virus E1E2 glycoproteins; SVGmu, Sindbis virus envelope glycoprotein; ampho MLV, amphotrophic murine leukemia virus; GP64, 
baculoviral-derived glycoprotein; hAAT, liver specific promoter human α1-antitrypsin; PGK, phosphoglycerate kinase; EF1α, eukaryotic 
translation elongation factor 1 alpha 1; EFS, short; SV40, simian virus 40 promoter; APOA-II, human liver-specific promoter Apolipoprotein  
A-II; ET, hepatocyte-specific chimeric promoter; SFFV, Spleen Focus-Forming Virus; CMV, Cytomegalovirus. 
 NILV Modification Disease/Application Envelope Promoter Transgene/Effector Target Ref. 
V
a
c
c
i
n
a
t
i
o
n
s
 
D64V West Nile Virus VSV-G CMV West Nile Virus Envelope Dendritic Cells [93] 
D64V Malaria 
VSV-G IND or NJ & 
Cocal Virus-G 
CMV 
Plasmodium yoelii Circumsporozoite 
Protein codon optimized 
Dendritic Cells [116] 
D64E Hepatitis C Virus HCV-E1E2-G CMV Hepatitis C Virus NS3 gene 
Antigen Presenting 
Cells 
[117] 
D116N Human Papillomavirus VSV-G CMV 
Human Papillomavirus 16  
E7-Calreticulin fusion 
Antigen Presenting 
Cells 
[118] 
D64V Thymoma SVGmu Ubiquitin-C 
Ovalbumin, melanoma antigen  
hgp100 and HIV-1 subtype B gag 
Dendritic Cells [119] 
D64V, N120L,  
W235E & Δatt Hepatitis B Virus VSV-G SFFV Hepatitis B Virus surface antigen Dendritic Cells [120] 
D116N 
Human Immunodeficiency 
Virus type 1 
VSV-G CMV HIV-1 JR-FL gp120 codon optimized 
Antigen Presenting 
Cells 
[114] 
C
e
l
l
-
T
y
p
e
 
D
i
f
f
e
r
e
n
t
i
a
t
i
o
n
 
D64V 
Purification of hESC  
derived progenitors 
VSV-G APOA-II Green Fluorescence Protein Hepatic Progenitors [121] 
D64V iPS Cell production VSV-G EF1α OCT4, SOX2, NANOG, LIN28,  
n-Myc and SV40 Large T Antigen 
Fibroblasts [122] 
D64N & D116N iPS Cell transgene excision VSV-G CMV Cre recombinase iPS Cells [123] 
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Table 1. Cont. 
NILV Modification Disease/Application Envelope Promoter Transgene/Effector Target Ref. 
S
i
t
e
-
D
i
r
e
c
t
e
d
 
I
n
t
e
g
r
a
t
i
o
n
 
D64V Retargetting HIV-1 ampho MLV SV40 
Integrase-E. coli LexA  
repressor fusion protein 
E. coli LexA recognition 
sites 
[124] 
D64V Directed Integration VSV-G SV40 
Integrase-Designed Polydactyl Zinc 
Finger Protein E2C fusion protein 
E2C-recognition sequence [125] 
D64V Directed Integration VSV-G PGK Yeast Flpx9 recombinase Flp-recognition sites [126] 
D64V 
Transposon mediated random 
integration 
VSV-G 
CMV, SFFV & 
SV40 
Sleeping Beauty Transposase/Transposase 
Expression Cassette 
Random Integration [127] 
D64V 
Homologous recombination mediated 
gene modification 
VSV-G N/A Calmegin targeting cassette Calmegin (clgn) gene [128] 
K264E, F185A, D116A, 
D64A & H12A 
Site-directed homologous 
recombination 
VSV-G CMV 
I-SceI Nuclease/Homologous 
recombination repair matrix 
I-SceI nuclease binding 
site 
[84] 
D64V Site-specific integration VSV-G PGK & SFFV Zinc Finger Nuclease/ZFN donor template ZFN-target site at IL2RG [129] 
D64V “Safe-site”-specific integration VSV-G 
SFFV, PGK & 
EF1α 
Zinc Finger Nuclease/ZFN donor 
template-GFP expression cassette 
CCR5 and AAVS1 loci [130] 
D64V Site-specific gene modification VSV-G EFS Zinc Finger Nuclease/ZFN donor template Adenosine Deaminase Locus [131] 
D64V Site-specific gene modification VSV-G CMV 
Transcription Activator-Like Effector 
Nucleases/TALEN donor template 
COL7A1 gene [132] 
P
e
r
s
i
s
t
e
n
t
 
E
p
i
s
o
m
a
l
 
E
x
p
r
e
s
s
i
o
n
 
D64V, N120L, W235E, 
Q148A, K264R & Δatt Stable gene transfer to muscle VSV-G SFFV Green Fluorescence Protein Muscle Tissue [61] 
D64E Stable gene transfer to liver and brain VSV-G CMV & hAAT Green Fluorescence Protein/Luciferase Brain & Liver Tissue [64] 
D64V Stable gene transfer to liver VSV-G PGK & ET Green Fluorescence Protein/Factor IX cDNA Hepatocytes [91] 
D64V Stable gene transfer to liver VSV-G ET Hyperfunctional coagulation factor IX Hepatocytes [133] 
D64V Stable gene transfer to retina and brain VSV-G CMV & SFFV Green Fluorescence Protein Ocular & Brain Tissue [89] 
D64E Stable gene transfer to brain VSV-G CMV Green Fluorescence Protein/Luciferase Brain Tissue [58] 
N region RRK motif to 
AAH  
Stable gene transfer to brain VSV-G CMV Green Fluorescence Protein Neural cells [62] 
D64V 
Stable gene transfer to central  
nervous system 
VSV-G, GP64 
& Rabies-G 
SFFV Green Fluorescence Protein Brain and Spinal Cord [63] 
D64V Stable gene transfer to spinal cord 
VSV-G & 
Rabies-G 
CMV Green Fluorescence Protein Spinal Cord [134] 
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Vaccination is an application where only transient expression is required and NILVs have been shown 
to stimulate an efficient and sustained immune response [112,119,135,136]. Preclinical studies of 
NILVs have demonstrated immune responses against human papillomavirus (HPV), malaria, HIV-1 
and the hepatitis B and C viruses [93,114,116–118,120] thus showing their potential for use in  
vaccine development. 
One application where transient expression is preferred over sustained expression is in cell 
reprogramming. This includes creation of induced pluripotent stem (iPS) cells and differentiation of 
iPS or embryonic stem (ES) cells into a lineage of interest. While somatic cells have been successfully 
reprogrammed into iPS cells using integrating vectors [137], the factors for inducing pluripotency are 
not necessary beyond initial reprogramming and constitutive expression of the factors has been shown 
to be harmful [137–140]. Continued expression can be oncogenic [140] and can also affect differentiation 
of iPS cells into other lineages [141]. Transgene free iPS cells have been produced using integrating 
LV followed by excision with NILVs after reprogramming [123] as well as by transient expression 
using both non-integrating adenoviral vectors [142,143] and NILV [122]. NILV have also been 
successful in differentiating ES cells into specific progenitors [121]. 
Another promising application for NILV is their use as templates for site-directed integration 
systems. A variety of systems are available that can direct integration to genomic “safe loci” or by 
altering the integration pattern to avoid transcriptional units with the hope of minimizing gene 
dysregulation. Integration can be directed to sequence-specific motifs in less intragenic regions by 
combining NILVs with an integrase protein fused to a DNA-binding protein such as the E. coli LexA 
repressor [124,144,145] or a synthetic polydactyl zinc finger protein E2C [125]. Another approach is 
combining recombinases or transposases transiently with NILV to facilitate integration at specific  
sites [126,127,146]. Third, NILVs can be designed to promote site specific homologous recombination 
(HR) [128]. Taking this a step farther, others have combined NILV with a rare cutting nuclease for 
targeted recombination at specific sites by HR [84]. Still others have used NILV as templates for HR 
along with engineered zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases 
(TALENs) [129–132]. Increasing clinical utility is expected as these systems are optimized to reduce 
off-target integrations and increase the efficiency of delivery.  
NILV have potential utility in cytotoxic cancer therapies. One approach takes advantage of 
abnormal expression levels of miRNA which are found in many tumor types [147]. In vitro and in vivo 
studies have shown miRNAs to have antitumorigenic properties [148]. Recent studies have shown the 
utility of non-integrating adeno-associated virus in suppressing tumor growth in lung [149,150] and 
liver cancers [151,152]. Non-integrating vectors offer the advantage of minimizing effects from 
transgene expression in normal cells. This targeting of miRNA provides the backdrop for developing 
NILV for similar applications. 
While there are many applications for transient expression of NILV, there is also great promise in 
their utilization for persistent episomal expression in non-proliferating post-mitotic cells. In this regard, 
NILV have been found to successfully provide long-lasting in vivo expression in several organs. 
Injections of integrase deficient LV and att site mutant NILV into mouse muscle were found to provide 
levels of transgene expression similar to wild-type LV for up three months post-transduction [61]. 
NILV have also been used to transduce the liver resulting in stable transgene expression for up to six 
months [64] and could provide therapeutic levels of transgene expression [91,133]. The retina 
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transduced with NILVs has been shown to provide transgene expression for up to nine months in  
mice [89]. NILV were used to successfully transduce the brain and spinal cord allowing for efficient 
transgene expression from 2 weeks up to 4 months post-transduction [58,62,63,89,134]. 
4. Conclusions 
A growing number of studies are demonstrating the potential utility of NILV in human gene 
therapy. Point mutations in integrase or the LTR att sites greatly reduce integration, and additional 
modifications to the vector or the target cell can further decrease illegitimate integration. Importantly, 
there have been a number of key studies that have optimized the expression of NILV. While further 
improvements are being evaluated, the current tools available are suitable for clinical use, and human 
trials could be conducted in the near future.  
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